Publicly-traded company Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) had a closing price of $8.20 yesterday. Meanwhile, the average 12-month price target from Wall Street analysts is currently $24.50, this means that the stock is underpriced by 66.53%. In the past 52 weeks the company’s stock price has moved within the range of $6.22 to $14.65.
This particular stock’s 5-day moving average is 8.04, its 20-day moving average is 7.81 and its 100-day moving average is 8.04. Spectrum Pharmaceuticals Inc. (SPPI) currently has 110.35M shares outstanding, which means that its market capitalization is $904.83M.
The Details: Spectrum Pharmaceuticals Inc. (SPPI) Financial Health
Return on Assets, which is expressed as a percentage, tells us how well a public company is using its assets to turn a profit. The larger the percentage, the better it is At the moment, Spectrum Pharmaceuticals Inc. Return on Assets is -44.80%.
What Does Wall Street Say about Company?
When selecting potential stocks to buy, many investors want to find out what Wall Street professionals are thinking about the company beforehand – like what the average analyst rating is. At the moment, the average analyst rating for SPPI is Buy. Out of 4 total analysts who were surveyed, 0 rated it a sell, 0 rated it a underweight, 0 rated it an overweight, 0 rated it hold, and 4 rated it a Buy.
Three months ago, on the other hand, the average analyst rating for Spectrum Pharmaceuticals Inc. (SPPI) was a Buy – from a survey of 5 analysts. Of the analysts who provided ratings, 0 rated the company a Hold, 0 rated it a Sell, 0 rated it an overweight, 0 rated it an underweight, and 5 rated it a Buy.
Understanding Profitability at Spectrum Pharmaceuticals Inc. (SPPI)
A good way of assessing a public company’s profitability is by looking at its Earnings per Share (EPS). In the most recent financial results released by Spectrum Pharmaceuticals Inc., for the quarter ending on 09/2019, the company posted EPS of -0.31. The average estimate of Wall Street analysts had projected -0.31.
Wall Street analysts, on average, are forecasting the company’s EPS to be -0.42, compared to -0.17 reported in the same quarter last year. When it comes to net revenue, the average estimate from a total of 4 analysts is 250k.